We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: orth America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Therapeutic indications
Adults
Prophylactic management in:
Mild asthma (PEF values greater than 80% predicted at baseline with less than 20% variability): Patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis.
Moderate asthma (PEF values 60-80% predicted at baseline with 20-30% variability): Patients
requiring regular asthma medication and patients with unstable or worsening asthma on other
prophylactic therapy or bronchodilator alone.
Severe asthma (PEF values less than 60% predicted at baseline with greater than 30% variability): Patients with severe chronic asthma. On transfer to high dose inhaled beclometasone dipropionate, many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or eliminate their requirement for oral corticosteroids.
Paediatric population (7-12 years)
Any child who requires prophylactic asthma medication
Dose and method of administration
Adults and children over 12 years of age
Patients should be given a starting dose of inhaled beclometasone dipropionate (BECLAZONE 50 micrograms CFC-Free Inhaler or BECLAZONE 100 micrograms CFC-Free Inhaler or BECLAZONE 250 micrograms CFC-Free Inhaler) which is appropriate for the severity of their disease based on the following guidance:
Mild asthma: 200 to 600mcg per day in divided doses.
Moderate asthma: 600 to 1000mcg per day in divided doses.
Severe asthma: Up to 1000mcg per day in divided doses.
The dose may then be adjusted until control is achieved or reduced to the minimum effective dose according to the individual response.
Paediatric population (7-12 years) Up to 200mcg per day in divided doses.
Children should be given a starting dose of inhaled beclometasone dipropionate which is appropriate for the severity of their disease. The dose may then be adjusted until control is achieved or reduced to the minimum effective dose according to the individual response. There are no data on the use of Beclazone CFC-Free Inhaler in children aged under seven years.
Method of administration
For inhalation use.
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
